Evidence map›Paper›PMID 26323873›Full record

ArticleBioorganic & medicinal chemistry letters2015

Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.

Federica Vannini, Andrew C MacKessack-Leitch, Erin K Eschbach, Mitali Chattopadhyay, Ravinder Kodela, Khosrow Kashfi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023
    Review
  2. Review
  3. Article
  4. Anticancer and Anti-Inflammatory Mechanisms of NOSH-Aspirin and Its Biological Effects.Computational and mathematical methods in medicine · 2022
    Review
  5. Article
  6. Review
  7. HJournal of experimental & clinical cancer research : CR · 2019
    Article
  8. Chemical Biology of HChemical reviews · 2018
    Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Federica VanniniDepartment of Physiology, Pharmacology and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA.
Andrew C MacKessack-LeitchDepartment of Physiology, Pharmacology and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA; EaStCHEM School of Chemistry, University of St. Andrews, St. Andrews, Fife KY16 9ST, UK.
Erin K EschbachDepartment of Physiology, Pharmacology and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA.
Mitali ChattopadhyayDepartment of Physiology, Pharmacology and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA.
Ravinder KodelaDepartment of Physiology, Pharmacology and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA.
Khosrow KashfiDepartment of Physiology, Pharmacology and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA; Avicenna Pharmaceuticals Inc., 555 West 57th Street, New York, NY 10019, USA. Electronic address: kashfi@med.cuny.edu.
New York Medical College · USCity University of New York · US

Funding

MIDARP at CCNYR24DA018055 · NIDA · CITY COLLEGE OF NEW YORK · PI FRIEDMAN, EITAN · 2005 to 2010
$2.2M
NIDA NIH HHS R24 DA018055
6 · The paper itself

Abstract

We recently reported the synthesis of NOSH-aspirin, a novel hybrid compound capable of releasing both nitric oxide (NO) and hydrogen sulfide (H2S). In NOSH-aspirin, the two moieties that release NO and H2S are covalently linked at the 1, 2 positions of acetyl salicylic acid, i.e., ortho-NOSH-aspirin. Here we report on the synthesis of meta- and para-NOSH-aspirins. We also made a head-to-head evaluation of the effects of these three positional isomers of NOSH-aspirin on colon cancer cell kinetics and induction of reactive oxygen species, which in recent years has emerged as a key event in causing cancer cell regression. Electron donating/withdrawing groups incorporated about the benzoate moiety significantly affected the potency of these compounds with respect to colon cancer cell growth inhibition.

Indexed as

Antineoplastic AgentsApoptosisAspirinCell CycleCell Line, TumorCell ProliferationDisulfidesDose-Response Relationship, DrugDrug Screening Assays, AntitumorHT29 CellsHumansHydrogen SulfideMolecular StructureNitratesNitric OxideReactive Oxygen Species4-(3-thioxo-3H-1,2-dithiol-5-yl)phenyl 2-((4-(nitrooxy)butanoyl)oxy)benzoateAntineoplastic AgentsAspirinDisulfidesHydrogen SulfideNitratesNitric OxideReactive Oxygen SpeciesCell kineticsColon cancerHydrogen sulfideNitric oxideNOSH-aspirinReactive oxygen species

Identifiers

PMID26323873
PMCPMC4592841
OpenAlexW1134178023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.